Sociedad Americana de Hirudoterapia

Monomeric and Oligomeric Decorsins of the Asian Medicinal Leech

Basic science / preclinical published in Int J Mol Sci (2025)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: In vitro / laboratoryGenómica y proteómicaFarmacología salivalDesarrollo de fármacosTolksdorf C et al. · International journal of molecular sciences, 2025

Abstract

Hematophagous leeches rely on a broad diversity of bioactive factors that interfere with the host's defense systems to secure a successful blood meal. The most prominent examples of such factors are the antithrombotics that address either the primary hemostasis (the platelet aggregation) or the secondary hemostasis (the blood coagulation). Whereas the inhibitors of platelet aggregation mainly cause continuous blood flow, coagulation inhibitors mainly keep the blood fluid within the stomach of the leech. The critical dependency of hematophagous leeches on the accurate action of all antithrombotic factors may explain the presence of multiple genes for each type of these factors that is regularly observed in leech genomes. The genome of Hirudinaria manillensis Lesson, 1842, the Asian buffalo leech, contains five individual genes that encode variants of the coagulation inhibitor hirudin. However, no genes that encode putative decorsins, the archetype of leech-derived inhibitors of platelet aggregation, have been described to date. Here, we report the identification of one monomeric and four multimeric decorsin encoding genes in the genome of H. manillensis. A selection of the putative decorsins was expressed as recombinant proteins, purified and functionally characterized. All but one of these putative decorsins displayed platelet aggregation-inhibitory potencies. Furthermore, we provide a mathematical calculation based on the mechanism of alternative pre-mRNA splicing that illustrates the potential to generate an enormous variety of different factors from one single multimeric ornatin gene.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsLeechesPlatelet AggregationAmino Acid SequenceHirudinsPhylogenyPlatelet Aggregation InhibitorsRecombinant Proteins

Resumen

Identification of one monomeric and four multimeric decorsin-encoding genes in Hirudinaria manillensis (Asian buffalo leech). Recombinant expression and functional verification of platelet-aggregation inhibition; mathematical model of alternative splicing diversity.

Por qué esto importa para la hirudoterapia

This study identified one monomeric and four multimeric decorsin-encoding genes in the genome of Hirudinaria manillensis (Asian buffalo leech), a species previously known to encode hirudin variants but not decorsins — the archetypal leech-derived platelet aggregation inhibitors. Selected putative decorsins were expressed as recombinant proteins, purified, and functionally characterized; all but one displayed platelet aggregation-inhibitory activity. The authors also mathematically modeled how alternative pre-mRNA splicing of multimeric ornatin genes could generate extensive molecular diversity. This work directly advances understanding of the leech secretome's antithrombotic repertoire and its genetic basis, core to ASH's domain. Caveat: Findings are preclinical, based on in vitro recombinant protein characterization; no clinical or in-vivo leech therapy data are presented.

Citación

Monomeric and Oligomeric Decorsins of the Asian Medicinal Leech.

Tolksdorf C et al. · International journal of molecular sciences, 2025

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.